CoChat

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study

Open access
de Vries, Elisabeth M. G., de Krijger, Manon, Färkkilä, Martti, Arola, Johanna, Schirmacher, Peter, Gotthardt, Daniel, Goeppert, Benjamin, Trivedi, Palak J., Hirschfield, Gideon M., Ytting, Henriette, Vainer, Ben, Buuren, Henk R. van, Biermann, Katharina, Harms, Maren H., Chazouilleres, Olivier, Wendum, Dominique, Kemgang, Astrid D., Chapman, Roger W., Wang, Lai Mun, Williamson, Kate D., Gouw, Annette S. H., Paradis, Valerie, Sempoux, Christine, Beuers, Ulrich, Hübscher, Stefan G., Verheij, Joanne, Ponsioen, Cyriel Y. · 2017 · Hepatology
Cited by 104

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated. We recently determined the applicability and prognostic value of three histological scoring systems in a single PSC cohort. The aim of this study was to validate their prognostic use and reproducibility across a multicenter PSC cohort. Liver biopsies from PSC patients were collected from seven European institutions. Histologic scoring was performed using the Nakanuma, Ishak, and Ludwig scoring systems. Biopsies were independently scored by six liver pathologists for interobserver agreement. The prognostic value of clinical, biochemical, and all three histologic scoring systems on predicting composite endpoints 1 (PSC‐related death and liver transplantation), 2 (liver transplantation), and 3 (liver‐related events), was assessed using univariable and multivariable Cox proportional hazards modeling. A total of 119 PSC patients were identified, and the median follow‐up was 142 months. During follow‐up, 31 patients died (20 PSC‐related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one or more liver‐related events. All three staging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [HR], 3.16 [95% confidence interval (CI), 1.49‐6.68] for endpoint 2 and HR, 2.05 [95% CI, 1.17‐3.57] for endpoint 3; Ishak system: HR, 1.55 [95% CI, 1.10‐2.18] for endpoint 2 and HR, 1.43 [95% CI, 1.10‐1.85] for endpoint 3; Ludwig system: HR, 2.62 [95% CI, 1.19‐5.80] for endpoint 2 and HR, 2.06 [95% CI, 1.09‐3.89] for endpoint 3). Only the Nakanuma staging system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22‐3.77). Interobserver agreement was moderate for Nakanuma stage (κ = 0.56) and substantial for Nakanuma component fibrosis (κ = 0.67), Ishak stage (κ = 0.64), and Ludwig stage (κ = 0.62). Conclusion: We confirm the independent prognostic value and demonstrate for the first time the reproducibility of staging disease progression in PSC using the Nakanuma, Ishak, and Ludwig staging systems. The Nakanuma staging system—incorporating features of chronic biliary disease—again showed the strongest predictive value. (H epatology 2017;65:907‐919).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28963

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
de Vries, E. M. G., de Krijger, M., Färkkilä, M., Arola, J., Schirmacher, P., Gotthardt, D., Goeppert, B., Trivedi, P. J., Hirschfield, G. M., Ytting, H., Vainer, B., Buuren, H. R. V., Biermann, K., Harms, M. H., Chazouilleres, O., Wendum, D., Kemgang, A. D., Chapman, R. W., Wang, L. M., Williamson, K. D., Gouw, A. S. H., Paradis, V., Sempoux, C., Beuers, U., Hübscher, S. G., Verheij, J., & Ponsioen, C. Y.
Venue
Hepatology
Published
2017-01-11
Volume
65
Issue
3
Pages
907-919
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2552444756
Cited by
104
References
15
FWCI
4.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.